Neuland Laboratories NEULANDLAB
Complex and peptide APIs plus custom manufacturing (CMS) for innovator molecules
Mapped in 1 theme: Pharmaceuticals.
Where Neuland Laboratories sits in the supply chain
Neuland Laboratories appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,559 | 1,477 | 2,023 |
| Net profit | 300 | 260 | 364 |
Latest-year revenue ₹2,023 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Peptide and complex-chemistry capability with a growing CMS book
- Strong five-year share-price gains on CMS wins
Risks
- CMS revenue is lumpy and tied to a few innovator molecules
- High valuation after a large re-rating
Common questions
What does Neuland Laboratories do?
Complex and peptide APIs plus custom manufacturing (CMS) for innovator molecules.
Where does Neuland Laboratories sit in the supply chain?
Neuland Laboratories (NSE: NEULANDLAB) is mapped in 2 supply-chain layers: APIs (active ingredients) (Pharmaceuticals) and CDMO & contract research (Pharmaceuticals).
Who are Neuland Laboratories' peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Divi's Laboratories, Laurus Labs, Aarti Drugs, Solara Active Pharma Sciences, Concord Biotech, Granules India and 2 more.
What is Neuland Laboratories' market cap and valuation?
As of 30 Oct 2026: market cap ₹25,280 Cr, P/E 50.8x, ROCE 26.5%, ROE 21.2%, dividend yield 0.17%.